• Marwan Bendixen posted an update 5 months, 2 weeks ago

    Our findings broaden the genetic heterogeneity and refine the clinical spectrum of DYNC1H1, and have implications for molecular diagnostics of motor neuron diseases. This article is protected by copyright. All rights reserved “”Summary.  Commonly known risk factors for infection with hepatitis C virus (HCV) include blood transfusion, injection drug use, intranasal cocaine use, and body tattoos. We hypothesized that Asian Americans infected with HCV may not identify with these established risk factors present in Caucasians and Hispanics, and our aim was to conduct a survey of risk factors in HCV-infected patients in these ethnic groups. In this prospective study, 494 patients infected with HCV completed a detailed risk assessment questionnaire at a liver centre in Northern California from 2001 to 2008. Among subjects participating in this AUY-922 solubility dmso study, 55% identified themselves as Caucasian, 20% as Hispanic, and 25% as Asian. Asian Americans were older, less likely to smoke or consume alcohol, and have a family history of cancer compared with Caucasians and Hispanics. The laboratory profiles were similar, and genotype 1 was the most common infection in all groups (74–75%). The great majority of Caucasians (94%) and Hispanics (86%) identified with commonly known risk factors, which was in contrast to 67% of Asians (P < 0.0001). The most common risk factors in Asians were blood transfusions (50%) and acupuncture (50%). Furthermore, 74% of Caucasians and 66% of Hispanics identified more than one major risk factor, while only 20% of Asians reported having more than one risk factor (P < 0.0001). Survey for established risk factors for acquisition of HCV may be more appropriate for risk assessment of Caucasians and Hispanics, but not for Asian Americans. These findings may guide the development of HCV screening in our increasingly diverse population. "”A combination of pegylated interferon and ribavirin presents standard of care (SOC) treatment for naïve chronic hepatitis C (CHC) patients with genotypes 1 and 3. In vitro studies demonstrated inhibitory effect of fluvastatin to hepatitis C virus (HCV) replication. In clinical trials combination of fluvastatin 20 mg daily and SOC improved sustained virological response (SVR) and significantly reduced viral relapse in CHC genotype 1 monoinfected patients. No studies were performed regarding the impact of fluvastatin on viral relapse in genotype 3 patients. The aim of this study was to investigate the impact of added fluvastatin to SOC on viral relapse in genotypes 1 and 3. The prospective study enrolled all over 162 naïve CHC genotypes 1 and 3 Caucasian patients, 64 in the study group that were treated with the combination of SOC and fluvastatin 80 mg daily, and 98 historical controls treated with SOC alone, matching the study group in genotype, age and gender.